Randomized controlled trial on the effects of ramipril and spironolactone on ventricular remodeling after an acute myocardial infarction;Ramipril vs espironolactona en el remodelamiento ventricular izquierdo post-infarto: Estudio randomizado y doble ciego

Revista Medica de Chile

Volumn 125, Issue 6, 1997, Pages 643-652

  Rodríguez V, José A ^a   Godoy J, Iván ^b   Castro G, Pablo ^b   Quintana F, Juan C ^b   Chávez S, Eduardo ^b   Yovanovich S, Jorge ^b   Corbalán H, Ramón ^b   Chávez R, Antonieta ^b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b NONE

Author keywords

Myocardial infarction; Ramipril; Randomized controlled trials; Spironolactone

Indexed keywords

ALDOSTERONE ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL; SPIRONOLACTONE;

ANALYSIS OF VARIANCE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART STROKE VOLUME; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ALDOSTERONE ANTAGONISTS; ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RAMIPRIL; SPIRONOLACTONE; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 0031150980     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. PFEFFER MA, LAMAS GA, VAUGHAN DE, PARISI AF, BRAUNWALD E. Effect of captopril on progressive ventricular dilatation after myocardial infarction. N Engl J Med 1988; 319: 80-6.
2. SHARPE N, SMITH H, MURPHY J, GREAVES S, HART H, GAMBLE G. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin converting-enzyme inhibition. Lancet 1991; 337: 872-6.
3. FOURTH INTERNATIONAL STUDY OF INFARCT SURVIVAL COLLABORATIVE GROUP. Fourth International Study of Infarct Survival: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-85.
4. PFEFFER MA, BRAUNWALD E, MOVE, ET AL. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial (SAVE). N Engl J Med 1992; 327: 669-77.
5. THE ACUTE INFARCTION RAMIPRIL EFFICACY (AIRE) STUDY INVESTIGATORS. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8.
6. GRUPPO ITALIANO PER LO STUDIO DELLA STREPTOCHINASI NELL'LNFARTO MIOCARDICO-3 (GISSI). GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on six-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-22.
7. KINGMA JH, VAN GILST WH, PEELS KH, ET AL. Acute intervention with captopril during thrombolysis in patients with acute myocardial infarction. Results from the Captopril and Thrombolysis Study (CATS). Eur Heart J 1994; 15: 898-907.
8. KOBER L, TORP-PEDERSEN C, CARLSEN JE, ET AL. A clinical trial of the angiotensin converting-enzime inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-6.
9. PFEFFER MA, BRAUNWALD E. Ventricular remodelling after myocardial infarction. Experimental observations and clinical implication. Circulation 1990; 81: 1161-72.
10. PFEFFER JM, PFEFFER MA, BRAUNWALD E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985; 57: 84-95.
11. MACDONALD KM, GARR M, CARLYLE PF, FRANCIS GS, HAUER K, HUNTER DW, PARISH T, STILLMAN A, COHN JN. Relative effects of α1-Adrenoceptor blockade, converting enzime inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog. Circulation 1994; 90: 3034.
12. BRILLA ET AL. Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res 1990; 76: 1355.
13. BRILLA CG, MATSUBARA LS, WEBER KT. Antialdosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyper-aldosteronism. J Moll Cell Cardiol 1993; 25: 563.
14. MICHEL JB. Left ventricular fibrosis in renovascular hypertensive rats. Effects of losartan and spironolactone. Hypertension 1995; 26: 101-11.
15. JALIL JE, JANICKI JS, PICK R, WEBER KT. Coronary vascular remodeling and myocardial fibrosis in the rat with renovascular hypertension: response to captopril. Am J Hypertens 1991; 4: 51.
16. SRIVASTAVA SC, STRAU RF. Blood Cell Labeling with 99m Tc: Progress and Perspectives. Semin Nucl Med 1990; 20: 41-51.
17. GORIS ML, BRAINDET PA. The Clinical and Mathematical Introduction to Computer Processing of Scintigrapbic Images. Raven Press, 1983.
18. MASSARDO T, RAMI A, GRENIER RP, SCHMIDT DH, PORT S. Left ventricular volume calculation using a count-based ratio method applied to multigated radionuclide angiography. Journal of Nuclear Medicine, April 1990.
19. BRAUNWALD E, PFEFFER MA. Ventricular enlargement and remodeling following acute myocardial infarction: Mechanisms and management. Am J Cardiol 1991; 68: 1D-6D.
20. KONSTAM MA, ROUSSEAU MF, KRONENBERG MW, UDELSON JE, MELIN J, STEWART D, DOLAN N, EDENS T, AHN S, METHERALL J, BENEDICT C, YUSUF F, POULER H. Effects of the angiotensin converting enzyme inhibitor Enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 1992; 86: 431-8.
21. GAUDRON P, EILLES C, KUGLER I, ERTL G. Progressive left ventricular disfunction and remodelling after myocardial infarction. Circulation 1993; 87: 755-63.
22. CHRISTIENSEN NJ, VIDEBAEK J. Plasma catecholamines and carbohydrate metabolism in patients with acute myocardial infarction. J Clin Invest 1974; 54: 278-86.
23. MCALPINE HM, MORTON JJ, LECKIE B, RUMLEY A, GILLEN G, DARGIE HJ. Neuroendocrine activation after acute myocardial infarction. Br Heart J 1988; 60: 117-24.
24. MICHOROWSKI B, CEREMUZYNSKI L. The renin-angiotensin-aldosterone system and the clinical course of acute myocardial infarction. Eur Heart J 1983; 4: 259-64.
25. GALIPEAU J, NEMER M, DROUIN J. Ventricular activation of the atrial natriuretic factor gene in acute myocardial infarction. N Engl J Med 1988; 319: 654-5.
26. TAN ACITL, VAN LOENHOUT TT, LAMFERS EJP, HOOGHOUDT THE, KLOPPENBORG PWC, BENRAAD TJ. Atrial Natriuretic peptide after myocardial infarction. Am Heart J 1989; 118: 490-4.
27. ROULEAU JL, MOYE LA, CHAMPAIN J, ET AL. Activation of Neurohormonal Systems following acute myocardial infarction. Am J Cardiol 1991; 687: 80D-86D.
28. ERIT G. Coronary vasoconstriction in experimental myocardial ischemia. J Cardiovasc Pharmacol 1987; 9 (Suppl 2): S9-S17.
29. GAVRAS H, KREMER D, DROWN JJ, ET AL. Angiotensin and nor-epinephrine induced myocardial lesions: experimental and clinical studies in rabbits and man. Am Heart J 1975; 89: 321-32.
30. MORGAN HE, BAKER KM: Cardiac hypertrophy: Mechanical, neural and endocrine dependence. Circulation 1991; 83: 13-25.
31. MEYER WJ, NICHOLS NR. Mineralocorticoid biding in cultured smooth muscle cells and fibroblasts from rat aorta. J Steroid Biochem 1981; 14: 1157-68.